Lawrence Erik Kurzius Purchases 10,000 Shares of Cooper Companies (NASDAQ:COO) Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Kurzius bought 10,000 shares of Cooper Companies stock in a transaction on Wednesday, September 16th. The shares were acquired at an average cost of $54.93 per share, with a total value of $549,300.00. Following the completion of the acquisition, the director owned 31,099 shares of the company’s stock, valued at $1,708,268.07. The trade was a 47.40% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 14th, Lawrence Kurzius purchased 10,000 shares of Cooper Companies stock. The shares were acquired at an average price of $53.91 per share, for a total transaction of $539,100.00.

Cooper Companies Trading Up 2.8%

Shares of COO stock opened at $55.29 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The company has a market cap of $10.51 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 2.19 and a beta of 0.82. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The firm has a fifty day moving average price of $69.92 and a 200-day moving average price of $68.68.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same period last year, the firm earned $0.49 EPS. Cooper Companies’s revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its board has authorized a share buyback plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

COO has been the subject of several analyst reports. Wells Fargo & Company set a $61.00 target price on shares of Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, September 10th. Zacks Research downgraded shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a report on Friday, September 11th. Piper Sandler lowered shares of Cooper Companies from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $86.00 to $59.00 in a research report on Thursday, September 10th. The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a research note on Wednesday, May 27th. Finally, Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a research report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $71.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avalon Trust Co bought a new stake in Cooper Companies in the second quarter worth $25,000. Root Financial Partners LLC raised its position in shares of Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. raised its position in shares of Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares in the last quarter. Elevation Wealth Partners LLC lifted its holdings in shares of Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC bought a new position in shares of Cooper Companies in the 2nd quarter valued at about $30,000. 24.39% of the stock is currently owned by institutional investors.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Activist investor Jana Partners urged Cooper to conduct an external CEO search, appoint a new board chair and evaluate asset sales. Although the campaign highlights execution problems, investors may view potential leadership and portfolio changes as catalysts for unlocking shareholder value. Reuters activist investor report
• Positive Sentiment: Several directors have recently bought shares, including Lawrence Kurzius’s purchase of 10,000 shares for approximately $549,300. The cluster of insider buying may signal that directors view the selloff as excessive. Director insider purchase report
• Positive Sentiment: Cooper retained CooperSurgical after its strategic review and expanded its share-repurchase authorization to $3 billion. The buyback, combined with reported record free cash flow and an adjusted EPS beat, supports the long-term shareholder-value case. Cooper Companies strategic review and capital plan article
• Neutral Sentiment: Jana’s campaign could lead to strategic improvements, but it also increases uncertainty around management, the board and Cooper’s business portfolio.
• Negative Sentiment: U.S. channel inventory destocking at CooperVision is expected to continue into the fourth quarter, raising questions about near-term demand and revenue growth. The company’s latest quarter beat EPS expectations but missed revenue estimates.
• Negative Sentiment: Investor-law-firm investigations related to the guidance reduction add legal and headline risk, while cautious analyst ratings and prior target-price cuts reflect Cooper’s underperformance versus medical-device peers. Securities investigation notice

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.